Ramping up and sustaining the production of vaccines
It is difficult to predict the nature of the next health threat. We do not know where, how or when it will hit. What we know is that playing catch is a lost battle.
Read moreRebuilding momentum on antibiotics research, giving innovators a chance to pull through
The pace of resistance to existing antibiotics is outpacing the rate at which new ones can reach the market and be used against difficult-to-treat infections.
Read more![](https://www.ifpma.org/wp-content/uploads/2022/11/expert-insight_221124-350x220.jpg)
Increasing access to medicines to support Universal Health Coverage
During the UN General Assembly this month and going forward, progress towards delivering Universal Health Coverage (UHC) will be front of stage. Achieving UHC was a commitment made as part of the 2030 Sustainable Development Goals (SDGs) when adopted in 2015 – so this year marks the half-way point in the journey towards 2030. If...
Read more![](https://www.ifpma.org/wp-content/uploads/2023/09/iStock-458660509-350x220.jpg)
Healthcare for all must be a goal shared by the global community
In September, some 200 Heads of State and top political decision-makers met in New York for the annual United Nations General Assembly. They recommitted to the UN Sustainable Development Goals (SDGs), with a political declaration pledging to “act with urgency to realize the [Agenda 2030] vision.” Halfway to 2030 and with the clock ticking, the renewal...
Read more![](https://www.ifpma.org/wp-content/uploads/2023/12/Woman-and-child_iStock_2023-purchase-350x220.jpg)
Global pharmaceutical industry welcomes new collaborative platform
IFPMA, the body representing the global research-based pharmaceutical industry, welcomes the creation of WIPO Re:Search, a new voluntary database for sharing intellectual property for R&D on medicines and vaccines for tuberculosis, malaria and neglected tropical diseases. WIPO Re:Search was launched today in Geneva by the World Intellectual Property Organisation (WIPO), and was followed by a...
Read moreGlobal Pharmaceutical industry findings published in two international peer
Vaccine supply data from 157 countries shows that global vaccination levels remain low; while policy measures that directly impact patients are linked to higher levels of Influenza Vaccination. Two studies being published this week in peer-reviewed journals look at global vaccination policies and use global vaccination provision data that had not been previously available. The...
Read moreNew report offers a blueprint to boost research and development (R&D)
10 May 2012, Geneva – A new study was released today reviewing initiatives to encourage research and development (R&D) for diseases such as HIV, tuberculosis, malaria and neglected tropical diseases. The report, titled “Assembling the pharmaceutical R&D puzzle for needs in the developing world,” introduces a blueprint based on six enabling factors that comprise: identification...
Read moreNew study highlights enabling factors for biopharmaceutical innovation in middle-income countries
Commissioned by IFPMA, the study identifies tailored, consistent long-term government policies as key factors to foster biopharmaceutical innovation An independent study on biopharmaceutical innovation in middle-income countries was released today at the 26 th IFPMA Assembly in Geneva. The report analyzed key national political and economic factors that foster biopharmaceutical innovation. The study, Policies that...
Read moreIFPMA highlights benefits of incremental innovation for global health
Biopharmaceutical incremental innovation increases therapeutic benefits and the number of treatment options available to healthcare providers and patients To better address patients’ needs, researchers constantly seek to reduce dosing frequency, improve tolerability of existing medicines, and minimize the potential for drug-drug interactions The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) today launches a new...
Read moreDr John C. Lechleiter, farewell remarks: chairman, president, and chief executive officer Eli Lilly
Dr John C. Lechleiter Chairman, President, and Chief Executive Officer Eli Lilly and Company and IFPMA President Farewell Remarks Global health conference “Investing for Healthier Societies: Innovation, Inclusiveness and Sustainability” that the IFPMA is hosting in partnership with Devex (4 November 2014, New York) (www.ifpmaassembly2014.org). Thank you, Eduardo, and good afternoon, everyone. It’s a pleasure...
Read more